Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pituitary adenylate cyclase-activating peptide: Potential roles in the pathophysiology and complications of cirrhosis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. HSD17B13 as a promising therapeutic target against chronic liver disease

    Research output: Contribution to journalEditorialResearchpeer-review

  4. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The burden of inflammatory bowel disease in Europe in 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: MR elastography can determine organ-related stiffness, which reflects the degree of fibrosis. Liver stiffness increases in cirrhosis, and stiffness increases further post-prandially due to increased portal blood in-flow. Non-selective beta-blockers (NSBB) reduce the portal venous inflow, but their effect on liver and spleen stiffness are disputed. Aims: To assess whether MR elastography of the liver or spleen reflects the severity of cirrhosis, whether treatment with NSBB changes liver and spleen stiffness and whether changes in stiffness can predict the effect of NSBB on portal pressure. Methods: Fifty-two patients with cirrhosis underwent liver vein catheterization and two-dimensional (2D) MR elastography on separate days. Thirty-six of the patients had a hepatic venous pressure gradient (HVPG) of ≥12 mmHg and were tested prior to, and after, intravenous infusion of NSBB using HVPG measurement and MR elastography. Results: HVPG showed a strong, positive, linear relationship with liver stiffness (r 2 = 0.92; P <.001) and spleen stiffness (r 2 = 0.94; P <.001). The cut-off points for identifying patients with a HVPG ≥ 12 mmHg were 7.7 kPa for liver stiffness (sensitivity 0.78, specificity 0.64) and 10.5 kPa for spleen stiffness (sensitivity 0.8, specificity 0.79). Intravenous administration of NSBB significantly decreased spleen stiffness by 6.9% (CI: 3.5-10.4, P <.001), but NSBB had no consistent effect on liver stiffness. However, changes in spleen stiffness were not related to the HVPG response (P =.75). Conclusions: Two-dimensional MR elastographic estimation of liver or spleen stiffness reflects the degree of portal hypertension in patients with liver cirrhosis, but changes in stiffness after NSBB do not predict the effect on HVPG.

Original languageEnglish
JournalLiver international : official journal of the International Association for the Study of the Liver
Volume41
Issue number9
Pages (from-to)2149-2158
Number of pages10
ISSN1478-3223
DOIs
Publication statusPublished - Sep 2021

    Research areas

  • beta-blockers, imaging, liver cirrhosis, magnetic resonance elastography, portal hypertension

ID: 65945836